Papers/PMID:16473858
Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.
BMJ (Clinical research ed.)2006The record
2 findings drawn from this paper, on 1 compound across 2 endpoints, 2 of them null.
What it reported
How to read these marksEvery finding here is a null result.
What did not
2 findings
melatonin — no detected effect on adverse event occurrence (oral or enteral supplement)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.FindingNull result“17 randomised controlled trials with 651 participants showed no evidence of adverse effects of melatonin with short term use (three months or less).”
Quoted verbatim from Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.. - Study
- meta-analysis
- Participants
- 651
- Population
- participants in randomised controlled trials of short-term melatonin (three months or less)
Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.2006PMID:16473858
melatonin — no detected effect on sleep onset latency
PreliminaryGrade D, Preliminary. Non-human or in vitro only.FindingNull result“Nine randomised controlled trials with 427 participants showed no evidence that melatonin had an effect on sleep onset latency in people who had sleep disorders accompanying sleep restriction (-1.0 (-2.3 to 0.3) min).”
Quoted verbatim from Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.. - Study
- meta-analysis
- Participants
- 427
- Population
- people with sleep disorders accompanying sleep restriction
Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis.2006PMID:16473858